for in a period the company's you, My transformational in The our participating Thank new today's XXXX in for was and thanks investors to a call. and also we interest chapter recently Troy. as and analysts for evolution. embarked exciting Kamada your year Kamada completed on
in dependence in market, to and XX approved to countries. with on completed strong specialty fixed product footprint now our assay over sales global as a have commercial plasma transition Takeda, integrated rapid our we capabilities sales as US importantly, historical company from well the Most diversified proprietary fully GLASSIA
financial year success met impressive strategic results, supported this XXXX shift by guidance. The full of annual which is our our
margins representing $XX and $XXX of EBITDA of achieved million, we million total revenue of XX%. Specifically, approximately
Our as EBITDA. revenue and growth of nearly what supporting million cash strong XX% December increase million represented in we it XXXX, performance to year which Moreover, record end $XX.X over in position XXXX operating to XXXX. is XXXX, during of Xx XXst, double as increase of the compared generated in our was cash at XXXX $XX a flow
Looking we throughout as to momentum enhance to with compared meaningfully the ahead, to year. last expect from extend XXXX further XXXX profitability
million represent approximately such, introducing As we year The and of XX% $XXX of XXXX are million $XX midpoint $XX profitability XXXX. guidance $XXX growth million over would revenue range that full of million. to to EBITDA of
positive including our Our in year portfolio sales in our impressive we and multiple acquired results XXXX has distribution and been the thriving outlook proprietary growth from royalties US, GLASSIA Takeda, the leverage the business. to XXXX, received FDA approved sales drivers, other IgGs of observed that full for markets, in product late of international this KEDRAB ability consequence Israeli in
driving upside This catalyst, revenue risk. which momentarily, further significant double-digit discuss limited growth with I downside our are potential significant annual and will
consisting IgG in for advancement VARIZIG and Most for on company. a search CYTOGAM, strategic of the and the a for was thorough assets approved the synergistic ideal full acquisition completed following XXXX FDA WINRHOSDF Kamada importantly, critical November HEPAGAM, the
of revenues to rapidly and XXXX US of increased establishment as the in as XXXX, generating professionals XX% year I'm year are report key full thrilled established of the XX% over who compared of full presence XXXX our team have that margins to acquired by During these and sales the deployed direct markets, of medical products in markets. operation a experienced part US-based affairs we gross
of progress direct good conventions. healthcare to engagement and at team practitioners in sales specialty promoting products portfolio opportunities US through other medical our plasma physicians The making is and
inquiries, clinical advocate to working scientific US. and major medical participating including is team affairs in medical while the in The the conferences physicians, addressing
a specialty first supported the these have time our over in by therapies been decades activities hyperimmune that represent market. important the products US As reminder, field-based these promoting activity in
from demand. feedback to by our key a will understanding physicians US to clinical positive continued encouraged continued new growth data received conducting believe related product to symposium who are publish We seeking impact this have on portfolio, are educational we the positive while contributing of that the in
of We expect to begin later this seeing activity the impact year.
Latin are America international product distribution Middle network grow East. primarily territories, leveraging new existing to our in and We strong also revenues the in
America year. $XX supply organization tender. these Latin contribute our in with XXXX million of this including these Both achievements procurement principally result securing an a key agreement $XX.X operating expansion products a of agreements million new for winning international Our and in VARIZIG Canadian for a will
are we course, and and in ahead commercial key are of significant with territories XXXX additional continuing encouraged highly strategic contracts in to beyond. Of the opportunities pursue us
assets. effort This standing these our commitment selling underscore supply agreement assumed to long proactive and leveraging to our distribution Kamada's strategic new relationships,
prophylaxis product, the is IgG CMV for disease with acquired is This therapy FDA-approved CYTOGAM, largest transplantation. its unique of organ and indicated four the only indication. proprietary Of the for product solid the associated
CYTOGAM notification the plant approval receive utilization manufacture our expect for mark successful facility will and to anticipated manufacture to plant conclusion submit The to a efficiency. technology The product and of to the the Israel our Behring. recently this transfer previous whether from will FDA ability CSL to by FDA approval in at We our impact positively the CYTOGAM process midyear. at manufacturer,
rabies annually. immunoglobulin. in move KEDRAB to continued past $XXX to on the which share Kedrion, the marketed is be significant market in our million In the US market year, gain KEDRAB, to by estimated US Let's
the XX% KEDRAB's XXXX will to margin I next differentiate in only the embedded it anticipate than commercial expansion helped the have Also what human rabies in more gross product to We Kamada. years. approval will level the US this also some in generates children. should clinically continue we significantly said that grow that products globally few product FDA of as reiterate be for over the previously, highlight for for the the successfully and first the studied obtained in leveraged team
XXXX Moving from on, began payments receiving during GLASSIA planned, we royalty as Takeda.
expect For range XXXX, income our generated grow $XX us will receive we and in and full of which help through million to to payments we cash $XX $XX.X annually million profitability million position. year the XXXX, royalty of
In in to the the sales international addition, of we continue local product market to partner. our grow
let's Now, ahead look catalysts. Plasma, I will a little farther company. US-based Kamada collection at with begin plasma future our
into Our early of plasma strategic correction XXXX supported entry product acquisition becoming US Houston, in company. goal plasma a and Texas fully-integrated Kamada of our the Collection Center Plasma represented market the specialty
centers to supply further to first capacity Last and of year, regular the enhance the our to [Indiscernible] plasma. advancing open are and in specialty we US our additional Hyperimmune collection currently plasma panel our expanded plan
efficacy our Let's ongoing evaluating product InnovAATe pivotal Phase AAT now X treatment clinical Inhaled of turn the for to of InnovAATe is deficiency. safety our and AAT the that trial
candidate be We to lung. promising the highly is AAT delivering over effective shown Inhaled the market substantial remain already be product the very annual A patient's to in in in a $X of potential EU. the in directly opportunity US excited product and that's this AAT transformational that about the into sales for exists billion
placebo-controlled trial, conducting InnovAATe currently clinical study. X We're a pivotal randomized double-blind Phase the
offering began we trial clinical and accelerate recruitment During now to enrolling sites seven patients. XXXX, with
trial November the DSMB Monitoring recommended In was continued the the in without addition, study Independent the Board, initiated. XXXX, Data since for fourth modification Safety the time
patients for the study for XX enrolled have The treatment, who period XX Leiden, treatment patients in trial first have already completed two-year Netherlands. including To-date, the been site
inclusion flow the Importantly, to-date accounting study events treatment the safety no level to reported include the to-date, on high adverse adherence based limitation. drug-related observed is air result patients also to criteria severe Moreover, and to patient with encouraging. would
XXXX, opportunities regulatory to Throughout continue to expediting EMA, shorten the progress we Agency, pathway. the meet Medicines the potential trial recruitment with and and European study and FDA discuss to intend to
Israel are our expertise Israeli leveraging strong Distribution markets and partners. XX segment, developed and our to products by international more our In market manufactured presence we and that in distribute than register are
recent grown multiple anticipate medical new we've our In pipeline to XXXX, launch therapies continuing distributed specialties. and of across products we years, in significantly
of planned of launched of upon XXXX approval is XX to annual focus in distribution regulatory products receipt of this biosimilar manufacturing this area peak and in Israeli more biosimilar expected a leader global sales than portfolio development several of be $XX a Alvotech, drugs. with eight business of years portfolio of strategic with An products launch within of anticipated the overall to distribution through agreement million. Included
in year significant for robust XXXX as value-creating revenue profitability the We've of substantial which plasma substantial rapid Kamada financial are progress in and specialty the potential was further XXXX achieved the leveraging growth summarize, upside by beyond. limited risk and and during well-positioned we to industry. we catalyst. leader global To multiple improvement, downside And
us. of growth in XXXX, based to on project continue foreseeable our past profitability multiple years looking catalysts, in and ahead the revenues double-digit Importantly, we annual
the I'll that, Chaime. With Chaime, to now over turn please. call
